CHI YOUNGOKCHI YOUNG OK11813OK, CHI YOUNGAssistant Professorprns:coAuthorOfcoauthor ofFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:similarTosimilar toprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierAddressvivo:address1address line 1vivo:addressCitycityvivo:addressPostalCodepostal codevivo:addressStatestate or provincevivo:authorInAuthorshipselected publicationsvivo:authorRankauthor rank in publicationAuthorshipDepartmentDivisionvivo:hasResearchArearesearch areasvivo:hrJobTitleHR job titleInformation Resourcevivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcevivo:mailingAddressmailing addressvivo:personInPositionpositionsPositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPerson24648050Ok CY, Xu-Monette ZY, Tzankov A, O'Malley DP, Montes-Moreno S, Visco C, M?ller MB, Dybkaer K, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Han van Krieken J, Ponzoni M, Farnen JP, Piris MA, Winter JN, Medeiros LJ, Young KHCancerPrevalence and clinical implications of cyclin D1 expression in diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program. Cancer. 2014 Jun 15; 120(12):1818-29.Cancer2014-03-19T00:00:002014Prevalence and clinical implications of cyclin D1 expression in diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program.HematopathologyLeukemiaMD AndersonKEN HEYOUNGKEN HE YOUNG9713YOUNG, KEN HEProfessorHAGOP MKANTARJIANHAGOP M KANTARJIAN8501KANTARJIAN, HAGOP MProfessorL JEFFREYMEDEIROSL JEFFREY MEDEIROS8762MEDEIROS, L JEFFREYProfessorSRDANVERSTOVSEKSRDAN VERSTOVSEK8781VERSTOVSEK, SRDANProfessorELIAS JOSEPHJABBOURELIAS JOSEPH JABBOUR9124JABBOUR, ELIAS JOSEPHAssociate ProfessorMARK JROUTBORTMARK J ROUTBORT9192ROUTBORT, MARK JAssociate ProfessorGUILLERMOGARCIA-MANEROGUILLERMO GARCIA-MANERO8853GARCIA-MANERO, GUILLERMOProfessorKEYUR PRAVINCHANDRAPATELKEYUR PRAVINCHANDRA PATEL9606PATEL, KEYUR PRAVINCHANDRAAssociate Professor21809995Hao S, Smith TW, Chu PG, Liu Q, Ok CY, Woda BA, Lu D, Lin P, Wang SA, Dresser K, Rock KL, Jiang ZArchives of pathology & laboratory medicineThe oncofetal protein IMP3: a novel molecular marker to predict aggressive meningioma. Arch Pathol Lab Med. 2011 Aug; 135(8):1032-6.Arch Pathol Lab Med2011-08-01T00:00:002011The oncofetal protein IMP3: a novel molecular marker to predict aggressive meningioma.22056910Ok CY, Singh RR, Vega FThe American journal of pathologyAberrant activation of the hedgehog signaling pathway in malignant hematological neoplasms. Am J Pathol. 2012 Jan; 180(1):2-11.Am J Pathol2011-11-01T00:00:002011Aberrant activation of the hedgehog signaling pathway in malignant hematological neoplasms.22585703Nardi V, Winkfield KM, Ok CY, Niemierko A, Kluk MJ, Attar EC, Garcia-Manero G, Wang SA, Hasserjian RPJournal of clinical oncology : official journal of the American Society of Clinical OncologyAcute myeloid leukemia and myelodysplastic syndromes after radiation therapy are similar to de novo disease and differ from other therapy-related myeloid neoplasms. J Clin Oncol. 2012 Jul 01; 30(19):2340-7.J Clin Oncol2012-05-14T00:00:002012Acute myeloid leukemia and myelodysplastic syndromes after radiation therapy are similar to de novo disease and differ from other therapy-related myeloid neoplasms.23787392Ok CY, Hasserjian RP, Fox PS, Stingo F, Zuo Z, Young KH, Patel K, Medeiros LJ, Garcia-Manero G, Wang SALeukemiaApplication of the international prognostic scoring system-revised in therapy-related myelodysplastic syndromes and oligoblastic acute myeloid leukemia. Leukemia. 2014 Jan; 28(1):185-9.Leukemia2013-06-21T00:00:002013Application of the international prognostic scoring system-revised in therapy-related myelodysplastic syndromes and oligoblastic acute myeloid leukemia.23649469Ok CY, Papathomas TG, Medeiros LJ, Young KHBloodEBV-positive diffuse large B-cell lymphoma of the elderly. Blood. 2013 Jul 18; 122(3):328-40.Blood2013-05-06T00:00:002013EBV-positive diffuse large B-cell lymphoma of the elderly.23660629Fu B, Ok CY, Goswami M, Xei W, Jaso JM, Muzzafar T, Bueso-Ramos C, Verstovsek S, Garcia-Manero G, Medeiros LJ, Wang SAAnnals of hematologyThe clinical importance of moderate/severe bone marrow fibrosis in patients with therapy-related myelodysplastic syndromes. Ann Hematol. 2013 Oct; 92(10):1335-43.Ann Hematol2013-05-10T00:00:002013The clinical importance of moderate/severe bone marrow fibrosis in patients with therapy-related myelodysplastic syndromes.21596435Ok CY, Medeiros LJ, Hu Y, Bueso-Ramos CE, Wang SALeukemia researchTransient/reversible ring sideroblasts in bone marrow of patients post cytotoxic therapies for primary malignancies. Leuk Res. 2011 Dec; 35(12):1605-10.Leuk Res2011-05-18T00:00:002011Transient/reversible ring sideroblasts in bone marrow of patients post cytotoxic therapies for primary malignancies.23987820Strati P, Manning JT, Ok CY, Garcia-Manero G, Estrov ZLeukemia & lymphomaInteraction between myelomonocytic and lymphoid cells in a patient with acute myelomonocytic leukemia and chronic lymphocytic leukemia. Leuk Lymphoma. 2014 Jun; 55(6):1425-7.Leuk Lymphoma2014-01-28T00:00:002014Interaction between myelomonocytic and lymphoid cells in a patient with acute myelomonocytic leukemia and chronic lymphocytic leukemia.24524924Ok CY, Yin CC, Yabe M, Bueso-Ramos CE, Miranda RN, Medeiros LJ, Konoplev SNClinical lymphoma, myeloma & leukemiaLymphoma with features intermediate between aggressive T-large granular lymphocytic leukemia and hepatosplenic T-cell lymphoma: a diagnostic dilemma? Clin Lymphoma Myeloma Leuk. 2014 Jun; 14(3):e95-e100.Clin Lymphoma Myeloma Leuk2014-01-02T00:00:002014Lymphoma with features intermediate between aggressive T-large granular lymphocytic leukemia and hepatosplenic T-cell lymphoma: a diagnostic dilemma?24583797Ok CY, Li L, Xu-Monette ZY, Visco C, Tzankov A, Manyam GC, Montes-Moreno S, Dybkaer K, Dybaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Chen J, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ai W, Ponzoni M, Ferreri AJ, Farnen JP, M?ller MB, Bueso-Ramos CE, Miranda RN, Winter JN, Piris MA, Medeiros LJ, Young KHClinical cancer research : an official journal of the American Association for Cancer ResearchPrevalence and clinical implications of epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countries. Clin Cancer Res. 2014 May 01; 20(9):2338-49.Clin Cancer Res2014-02-28T00:00:002014Prevalence and clinical implications of epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countries.24685107Ok CY, Wang SA, Amin HMClinical lymphoma, myeloma & leukemiaLeukemic phase of ALK(+) anaplastic large-cell lymphoma, small-cell variant: clinicopathologic pitfalls of a rare entity. Clin Lymphoma Myeloma Leuk. 2014 Aug; 14(4):e123-6.Clin Lymphoma Myeloma Leuk2014-03-02T00:00:002014Leukemic phase of ALK(+) anaplastic large-cell lymphoma, small-cell variant: clinicopathologic pitfalls of a rare entity.25124685Ok CY, Chen J, Xu-Monette ZY, Tzankov A, Manyam GC, Li L, Visco C, Montes-Moreno S, Dybk?r K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Zhao X, Ponzoni M, Ferreri AJ, Bertoni F, Farnen JP, M?ller MB, Piris MA, Winter JN, Medeiros LJ, Young KHClinical cancer research : an official journal of the American Association for Cancer ResearchClinical implications of phosphorylated STAT3 expression in De Novo diffuse large B-cell lymphoma. Clin Cancer Res. 2014 Oct 01; 20(19):5113-23.Clin Cancer Res2014-08-14T00:00:002014Clinical implications of phosphorylated STAT3 expression in De Novo diffuse large B-cell lymphoma.25573287Ok CY, Patel KP, Garcia-Manero G, Routbort MJ, Fu B, Tang G, Goswami M, Singh R, Kanagal-Shamanna R, Pierce SA, Young KH, Kantarjian HM, Medeiros LJ, Luthra R, Wang SALeukemia researchMutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases. Leuk Res. 2015 Mar; 39(3):348-54.Leuk Res2014-12-20T00:00:002014Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases.25613729Ok CY, Li L, Young KHExperimental & molecular medicineEBV-driven B-cell lymphoproliferative disorders: from biology, classification and differential diagnosis to clinical management. Exp Mol Med. 2015 Jan 23; 47:e132.Exp Mol Med2015-01-23T00:00:002015EBV-driven B-cell lymphoproliferative disorders: from biology, classification and differential diagnosis to clinical management.25952993Ok CY, Patel KP, Garcia-Manero G, Routbort MJ, Peng J, Tang G, Goswami M, Young KH, Singh R, Medeiros LJ, Kantarjian HM, Luthra R, Wang SAJournal of hematology & oncologyTP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases. J Hematol Oncol. 2015 May 08; 8:45.J Hematol Oncol2015-05-08T00:00:002015TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases.26101854Ok CY, Ye Q, Li L, Manyam GC, Deng L, Goswami RR, Wang X, Montes-Moreno S, Visco C, Tzankov A, Dybkaer K, Zhang L, Abramson J, Sohani AR, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Zhang S, Parsons BM, Xu M, M?ller MB, Winter JN, Piris MA, Xu-Monette ZY, Medeiros LJ, Young KHOncotargetAge cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma--is it necessary? Oncotarget. 2015 Jun 10; 6(16):13933-45.Oncotarget2015-06-10T00:00:002015Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma--is it necessary?26111978Ok CY, Xu-Monette ZY, Li L, Manyam GC, Montes-Moreno S, Tzankov A, Visco C, Dybk?r K, Routbort MJ, Zhang L, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Parsons BM, Rao H, M?ller MB, Winter JN, Piris MA, Wang SA, Medeiros LJ, Young KHModern pathology : an official journal of the United States and Canadian Academy of Pathology, IncEvaluation of NF-?B subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functions. Mod Pathol. 2015 Sep; 28(9):1202-13.Mod Pathol2015-06-26T00:00:002015Evaluation of NF-?B subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functions.26187891Ok CY, Young KHAgingAge cutoff in lymphoma diagnosis. Aging (Albany NY). 2015 Jul; 7(7):451-2.Aging (Albany NY)2015-07-01T00:00:002015Age cutoff in lymphoma diagnosis.26243778Wang W, Cortes JE, Lin P, Beaty MW, Ai D, Amin HM, McDonnell TJ, Ok CY, Kantarjian HM, Medeiros LJ, Hu SBloodClinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors. Blood. 2015 Oct 01; 126(14):1699-706.Blood2015-08-04T00:00:002015Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors.26324762Li L, Xu-Monette ZY, Ok CY, Tzankov A, Manyam GC, Sun R, Visco C, Zhang M, Montes-Moreno S, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, M?ller MB, Wang J, Parsons BM, Winter JN, Piris MA, Pham LV, Medeiros LJ, Young KHOncotargetPrognostic impact of c-Rel nuclear expression and REL amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma. Oncotarget. 2015 Sep 15; 6(27):23157-80.Oncotarget2015-09-15T00:00:002015Prognostic impact of c-Rel nuclear expression and REL amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma.26382622Ohanian M, Bueso-Ramos C, Ok CY, Lin P, Patel K, Alattar ML, Khoury JD, Rozovski U, Estrov Z, Huh YO, Cortes J, Abruzzo LVCancer geneticsAcute myeloid leukemia with MYC rearrangement and JAK2 V617F mutation. Cancer Genet. 2015 Nov; 208(11):571-4.Cancer Genet2015-06-25T00:00:002015Acute myeloid leukemia with MYC rearrangement and JAK2 V617F mutation.26386082Yabe M, Medeiros LJ, Wang SA, Konoplev S, Ok CY, Loghavi S, Lu G, Flores L, Khoury JD, Cason RC, Young KH, Miranda RNAmerican journal of clinical pathologyClinicopathologic, Immunophenotypic, Cytogenetic, and Molecular Features of ?d T-Cell Large Granular Lymphocytic Leukemia: An Analysis of 14 Patients Suggests Biologic Differences With a? T-Cell Large Granular Lymphocytic Leukemia. [corrected]. Am J Clin Pathol. 2015 Oct; 144(4):607-19.Am J Clin Pathol2015-10-01T00:00:002015Clinicopathologic, Immunophenotypic, Cytogenetic, and Molecular Features of ?d T-Cell Large Granular Lymphocytic Leukemia: An Analysis of 14 Patients Suggests Biologic Differences With a? T-Cell Large Granular Lymphocytic Leukemia. [corrected].74Professor10Assistant Professor14Associate Professor1515 Holcombe BlvdHouston77030-4009TX4.320110.0126237314research areas4.776790.025993479coauthor of232.36828.643660similar to11110selected publicationsSANAMLOGHAVISANAM LOGHAVI11842LOGHAVI, SANAMAssistant ProfessorAuthorship 3725751Authorship 3725762Authorship 3725771Authorship 3725781Authorship 3725793Authorship 3725801Authorship 3727075Authorship 3727081Authorship 3727091Authorship 3727101Authorship 3727113Authorship 3727121Authorship 3727131Authorship 3727145Authorship 844308Authorship 846854Authorship 847246Authorship 848631Authorship 850177Authorship 851735Authorship 853805Authorship 856445Authorship 858616Authorship 860270Authorship 863007Authorship 864942Authorship 868097Authorship 868191AgingAge cutoff in lymphoma diagnosis. Aging. 7:451-452.Age cutoff in lymphoma diagnosisAmerican Journal of Clinical PathologyDetection of an abnormal myeloid clone by flow cytometry in familial platelet disorder with propensity to myeloid malignancy. American Journal of Clinical Pathology. 145:271-276.Detection of an abnormal myeloid clone by flow cytometry in familial platelet disorder with propensity to myeloid malignancyLeukemiaLoss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma. Leukemia. Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphomaSingle-cell quantitative PCR. 153-159.Single-cell quantitative PCROncotargetPrognostic impact of c-Rel nuclear expression and REL amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma. Oncotarget. 6:23157-23180.Prognostic impact of c-Rel nuclear expression and REL amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphomaAmerican Journal of Clinical PathologyMyeloproliferative neoplasms with calreticulin mutations exhibit distinctive morphologic features. American Journal of Clinical Pathology. 145:418-427.Myeloproliferative neoplasms with calreticulin mutations exhibit distinctive morphologic featuresJournal of Clinical OncologyRelapsed refractory BRAF-negative, IGHV4-34-positive variant of hairy cell leukemia. Journal of Clinical Oncology. 34:e57-e60.Relapsed refractory BRAF-negative, IGHV4-34-positive variant of hairy cell leukemiaOncotargetAge cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma-is it necessary?. Oncotarget. 6:13933-13945.Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma-is it necessary?Cancer geneticsAcute myeloid leukemia with MYC rearrangement and JAK2 V617F mutation. Cancer genetics. 208:571-574.Acute myeloid leukemia with MYC rearrangement and JAK2 V617F mutationModern PathologyEvaluation of NF-κB subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functions. Modern Pathology. 28:1202-1213.Evaluation of NF-κB subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functionsOncotargetAge cutoff for epstein-barr virus-positive diffuse large B-cell lymphoma - is it necessary?. Oncotarget. 6:13935-13946.Age cutoff for epstein-barr virus-positive diffuse large B-cell lymphoma - is it necessary?Clinical Cancer ResearchErratum. Clinical Cancer Research. 20:4974.ErratumJournal of Hematology and OncologyTP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases. Journal of Hematology and Oncology. 8.TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseasesBloodClinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors. Blood. 126:1699-1706.Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitorsAuthorship 8868891Authorship 8872233Authorship 8873441Authorship 8874411Authorship 8874931Authorship 8875893Authorship 8882081Authorship 8882251Authorship 8886348D009154Physiology2018151490.239339MutationD016403Disorders27716600.457442Lymphoma, Large B-Cell, DiffuseD020522Disorders1587130.642931Lymphoma, Mantle-CellD009190Disorders29529700.382934Myelodysplastic SyndromesAuthorship 9014142Authorship 9035442Authorship 9044791Authorship 9057121Authorship 9083533Authorship 9092021Authorship 91534912Authorship 9165257Authorship 9214183Authorship 92143210Authorship 9224654Authorship 9224696Authorship 9232321Authorship 9282758Authorship 9302046Authorship 9308511Authorship 9309141Authorship 93261315Authorship 9337626D020031Disorders1784920.696045Epstein-Barr Virus Infections22646275Yu H, Ok CY, Hesse A, Nordell P, Connor D, Sjostedt E, Pechet L, Snyder LMArchives of pathology & laboratory medicineEvaluation of an automated digital imaging system, Nextslide Digital Review Network, for examination of peripheral blood smears. Arch Pathol Lab Med. 2012 Jun; 136(6):660-7.Arch Pathol Lab Med2012-06-01T00:00:002012Evaluation of an automated digital imaging system, Nextslide Digital Review Network, for examination of peripheral blood smears.25412846Cleven AH, Nardi V, Ok CY, Goswami M, Dal Cin P, Zheng Z, Iafrate AJ, Abdul Hamid MA, Wang SA, Hasserjian RPModern pathology : an official journal of the United States and Canadian Academy of Pathology, IncHigh p53 protein expression in therapy-related myeloid neoplasms is associated with adverse karyotype and poor outcome. Mod Pathol. 2015 Apr; 28(4):552-63.Mod Pathol2014-11-21T00:00:002014High p53 protein expression in therapy-related myeloid neoplasms is associated with adverse karyotype and poor outcome.24982452Jain P, Ok CY, Konoplev S, Patel KP, Jorgensen J, Estrov Z, Luthra R, Kantarjian H, Ravandi FJournal of clinical oncology : official journal of the American Society of Clinical OncologyRelapsed Refractory BRAF-Negative, IGHV4-34-Positive Variant of Hairy Cell Leukemia: A Distinct Entity? J Clin Oncol. 2016 Mar 01; 34(7):e57-60.J Clin Oncol2014-06-30T00:00:002014Relapsed Refractory BRAF-Negative, IGHV4-34-Positive Variant of Hairy Cell Leukemia: A Distinct Entity?26843054Ok CY, Singh RR, Salim AAMethods in molecular biology (Clifton, N.J.)Single-Cell Quantitative PCR: Advances and Potential in Cancer Diagnostics. Methods Mol Biol. 2016; 1392:153-9.Methods Mol Biol2016-01-01T00:00:002016Single-Cell Quantitative PCR: Advances and Potential in Cancer Diagnostics.26800764Ok CY, Leventaki V, Wang SA, Dinardo C, Medeiros LJ, Konoplev SAmerican journal of clinical pathologyDetection of an Abnormal Myeloid Clone by Flow Cytometry in Familial Platelet Disorder With Propensity to Myeloid Malignancy. Am J Clin Pathol. 2016 Feb; 145(2):271-6.Am J Clin Pathol2016-01-22T00:00:002016Detection of an Abnormal Myeloid Clone by Flow Cytometry in Familial Platelet Disorder With Propensity to Myeloid Malignancy.28494520Wang W, Routbort MJ, Ok CY, Patel KP, Sun Y, Kanagal-Shamanna R, Medeiros LJ, Wang SAAmerican journal of hematologyCharacterization of TP53 mutations in clonal cytopenia of undetermined significance. Am J Hematol. 2017 Aug; 92(8):E175-E177.Am J Hematol2017-06-09T00:00:002017Characterization of TP53 mutations in clonal cytopenia of undetermined significance.28482851Ok CY, Young KHJournal of hematology & oncologyCheckpoint inhibitors in hematological malignancies. J Hematol Oncol. 2017 05 08; 10(1):103.J Hematol Oncol2017-05-08T00:00:002017Checkpoint inhibitors in hematological malignancies.28281555Cai Q, Tu M, Xu-Monette ZY, Sun R, Manyam GC, Xu X, Tzankov A, Hsi ED, M?ller MB, Medeiros LJ, Ok CY, Young KHModern pathology : an official journal of the United States and Canadian Academy of Pathology, IncNF-?B p50 activation associated with immune dysregulation confers poorer survival for diffuse large B-cell lymphoma patients with wild-type p53. Mod Pathol. 2017 06; 30(6):854-876.Mod Pathol2017-03-10T00:00:002017NF-?B p50 activation associated with immune dysregulation confers poorer survival for diffuse large B-cell lymphoma patients with wild-type p53.28242522Ok CY, Young KHCancer treatment reviewsTargeting the programmed death-1 pathway in lymphoid neoplasms. Cancer Treat Rev. 2017 Mar; 54:99-109.Cancer Treat Rev2017-02-11T00:00:002017Targeting the programmed death-1 pathway in lymphoid neoplasms.28926144Wang W, Routbort MJ, Tang Z, Ok CY, Patel KP, Daver N, Garcia-Manero G, Medeiros LJ, Wang SAEuropean journal of haematologyCharacterization of TP53 mutations in low-grade myelodysplastic syndromes and myelodysplastic syndromes with a non-complex karyotype. Eur J Haematol. 2017 Dec; 99(6):536-543.Eur J Haematol2017-10-20T00:00:002017Characterization of TP53 mutations in low-grade myelodysplastic syndromes and myelodysplastic syndromes with a non-complex karyotype.28927162Margolskee E, Hasserjian RP, Hassane D, Tam W, Mathew S, Ok CY, Wang SA, Oak J, Arber DA, Orazi AAmerican journal of clinical pathologyMyelodysplastic Syndrome, Unclassifiable (MDS-U) With 1% Blasts Is a Distinct Subgroup of MDS-U With a Poor Prognosis. Am J Clin Pathol. 2017 Jul 01; 148(1):49-57.Am J Clin Pathol2017-07-01T00:00:002017Myelodysplastic Syndrome, Unclassifiable (MDS-U) With 1% Blasts Is a Distinct Subgroup of MDS-U With a Poor Prognosis.29740811Romaguera JE, Lee HJ, Tarapore R, Prabhu V, Allen J, Schalop L, Zloza A, Ok CY, Sadimin ET, Schenkel J, Badillo M, Wang MBritish journal of haematologyIntegrated stress response and immune cell infiltration in an ibrutinib-refractory mantle cell lymphoma patient following ONC201 treatment. Br J Haematol. 2019 04; 185(1):133-136.Br J Haematol2018-05-08T00:00:002018Integrated stress response and immune cell infiltration in an ibrutinib-refractory mantle cell lymphoma patient following ONC201 treatment.29492206Quesada AE, Hu Z, Routbort MJ, Patel KP, Luthra R, Loghavi S, Zuo Z, Yin CC, Kanagal-Shamanna R, Wang SA, Jorgensen JL, Medeiros LJ, Ok CYOncotargetMixed phenotype acute leukemia contains heterogeneous genetic mutations by next-generation sequencing. Oncotarget. 2018 Feb 02; 9(9):8441-8449.Oncotarget2018-01-03T00:00:002018Mixed phenotype acute leukemia contains heterogeneous genetic mutations by next-generation sequencing.30117174Mi X, Griffin G, Lee W, Patel S, Ohgami R, Ok CY, Wang S, Geyer JT, Xiao W, Roshal M, Garcia JS, Silverman LB, Sallan SE, Aster JC, Harris MH, Weinberg OKAmerican journal of hematologyGenomic and clinical characterization of B/T mixed phenotype acute leukemia reveals recurrent features and T-ALL like mutations. Am J Hematol. 2018 11; 93(11):1358-1367.Am J Hematol2018-09-26T00:00:002018Genomic and clinical characterization of B/T mixed phenotype acute leukemia reveals recurrent features and T-ALL like mutations.30171025Ok CY, Loghavi S, Sui D, Wei P, Kanagal-Shamanna R, Yin CC, Zuo Z, Routbort MJ, Tang G, Tang Z, Jorgensen JL, Luthra R, Ravandi F, Kantarjian HM, DiNardo CD, Medeiros LJ, Wang SA, Patel KPHaematologicaPersistent IDH1/2 mutations in remission can predict relapse in patients with acute myeloid leukemia. Haematologica. 2019 02; 104(2):305-311.Haematologica2018-08-31T00:00:002018Persistent IDH1/2 mutations in remission can predict relapse in patients with acute myeloid leukemia.30175400Jain P, Kanagal-Shamanna R, Zhang S, Ahmed M, Ghorab A, Zhang L, Ok CY, Li S, Hagemeister F, Zeng D, Gong T, Chen W, Badillo M, Nomie K, Fayad L, Medeiros LJ, Neelapu S, Fowler N, Romaguera J, Champlin R, Wang L, Wang MLBritish journal of haematologyLong-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib. Br J Haematol. 2018 11; 183(4):578-587.Br J Haematol2018-09-02T00:00:002018Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib.30181564Ok CY, Medeiros LJ, Thakral B, Tang G, Jain N, Jabbour E, Pierce SA, Konoplev SModern pathology : an official journal of the United States and Canadian Academy of Pathology, IncHigh-grade B-cell lymphomas with TdT expression: a diagnostic and classification dilemma. Mod Pathol. 2019 01; 32(1):48-58.Mod Pathol2018-09-04T00:00:002018High-grade B-cell lymphomas with TdT expression: a diagnostic and classification dilemma.30086334Garces S, Khoury JD, Kanagal-Shamanna R, Salem A, Wang SA, Ok CY, Hu S, Patel KP, Routbort MJ, Luthra R, Tang G, Schlette EJ, Bueso-Ramos CE, Medeiros LJ, Loghavi SHuman pathologyChronic lymphocytic leukemia with proliferation centers in bone marrow is associated with younger age at initial presentation, complex karyotype, and TP53 disruption. Hum Pathol. 2018 12; 82:215-231.Hum Pathol2018-08-04T00:00:002018Chronic lymphocytic leukemia with proliferation centers in bone marrow is associated with younger age at initial presentation, complex karyotype, and TP53 disruption.30577887Patel KP, Ruiz-Cordero R, Chen W, Routbort MJ, Floyd K, Rodriguez S, Galbincea J, Barkoh BA, Hatfield D, Khogeer H, Kanagal-Shamanna R, Yin CC, Zuo Z, Loghavi S, Ok CY, DiNardo CD, Luthra R, Medeiros LJThe Journal of molecular diagnostics : JMDUltra-Rapid Reporting of GENomic Targets (URGENTseq): Clinical Next-Generation Sequencing Results within 48?Hours of Sample Collection. J Mol Diagn. 2019 01; 21(1):89-98.J Mol Diagn2019-01-01T00:00:002019Ultra-Rapid Reporting of GENomic Targets (URGENTseq): Clinical Next-Generation Sequencing Results within 48?Hours of Sample Collection.Authorship 941774530802809O'Malley DP, Dogan A, Fedoriw Y, Medeiros LJ, Ok CY, Salama MEAnnals of diagnostic pathologyAmerican Registry of Pathology Expert Opinions: Immunohistochemical evaluation of classic Hodgkin lymphoma. Ann Diagn Pathol. 2019 Apr; 39:105-110.Ann Diagn Pathol2019-02-06T00:00:002019American Registry of Pathology Expert Opinions: Immunohistochemical evaluation of classic Hodgkin lymphoma.Authorship 9431361230924136Hu B, Patel KP, Chen HC, Wang X, Wang F, Luthra R, Routbort MJ, Kanagal-Shamanna R, Medeiros LJ, Yin CC, Zuo Z, Ok CY, Loghavi S, Tang G, Tambaro FP, Thompson P, Burger J, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating MJ, Wierda WGBritish journal of haematologyRoutine sequencing in CLL has prognostic implications and provides new insight into pathogenesis and targeted treatments. Br J Haematol. 2019 06; 185(5):852-864.Br J Haematol2019-03-28T00:00:002019Routine sequencing in CLL has prognostic implications and provides new insight into pathogenesis and targeted treatments.Authorship 9445061030963592Quesada AE, Routbort MJ, DiNardo CD, Bueso-Ramos CE, Kanagal-Shamanna R, Khoury JD, Thakral B, Zuo Z, Yin CC, Loghavi S, Ok CY, Wang SA, Tang Z, Bannon SA, Benton CB, Garcia-Manero G, Kantarjian H, Luthra R, Medeiros LJ, Patel KPAmerican journal of hematologyDDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high-risk disease. Am J Hematol. 2019 07; 94(7):757-766.Am J Hematol2019-05-07T00:00:002019DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high-risk disease.Authorship 945227431000771Weinberg OK, Hasserjian RP, Baraban E, Ok CY, Geyer JT, Philip JKSS, Kurzer JH, Rogers HJ, Nardi V, Stone RM, Garcia JS, Hsi ED, Bagg A, Wang SA, Orazi A, Arber DAModern pathology : an official journal of the United States and Canadian Academy of Pathology, IncClinical, immunophenotypic, and genomic findings of acute undifferentiated leukemia and comparison to acute myeloid leukemia with minimal differentiation: a study from the bone marrow pathology group. Mod Pathol. 2019 09; 32(9):1373-1385.Mod Pathol2019-04-18T00:00:002019Clinical, immunophenotypic, and genomic findings of acute undifferentiated leukemia and comparison to acute myeloid leukemia with minimal differentiation: a study from the bone marrow pathology group.Authorship 9474669Authorship 9474777Authorship 947938231115909Khogeer H, Rahman H, Jain N, Angelova EA, Yang H, Quesada A, Ok CY, Sui D, Wei P, Al Fattani A, Pierce S, Loghavi S, Lamb A, Hu P, Thakral B, Kanagal-Shamanna R, Jorgensen JL, Jabbour EJ, Kantarjian HM, Medeiros LJ, Khoury JDBritish journal of haematologyEarly T precursor acute lymphoblastic leukaemia/lymphoma shows differential immunophenotypic characteristics including frequent CD33 expression and in vitro response to targeted CD33 therapy. Br J Haematol. 2019 08; 186(4):538-548.Br J Haematol2019-05-22T00:00:002019Early T precursor acute lymphoblastic leukaemia/lymphoma shows differential immunophenotypic characteristics including frequent CD33 expression and in vitro response to targeted CD33 therapy.31109591Tang Z, Tang G, Hu S, Patel KP, Yin CC, Wang W, Lin P, Toruner GA, Ok CY, Gu J, Lu X, Khoury JD, Medeiros LJCancer geneticsDeciphering the complexities of MECOM rearrangement-driven chromosomal aberrations. Cancer Genet. 2019 04; 233-234:21-31.Cancer Genet2019-03-11T00:00:002019Deciphering the complexities of MECOM rearrangement-driven chromosomal aberrations.31132650Sakhdari A, Ok CY, Patel KP, Kanagal-Shamanna R, Yin CC, Zuo Z, Hu S, Routbort MJ, Luthra R, Medeiros LJ, Khoury JD, Loghavi SAnnals of diagnostic pathologyTP53 mutations are common in mantle cell lymphoma, including the indolent leukemic non-nodal variant. Ann Diagn Pathol. 2019 Aug; 41:38-42.Ann Diagn Pathol2019-05-16T00:00:002019TP53 mutations are common in mantle cell lymphoma, including the indolent leukemic non-nodal variant.Authorship 949069931193989Tang Z, Tang G, Hu S, Patel KP, Cameron Yin C, Wang W, Lin P, Toruner GA, Ok CY, Gu J, Lu X, Khoury JD, Jeffrey Medeiros LData in briefData on MECOM rearrangement-driven chromosomal aberrations in myeloid malignancies. Data Brief. 2019 Jun; 24:104025.Data Brief2019-05-23T00:00:002019Data on MECOM rearrangement-driven chromosomal aberrations in myeloid malignancies.Authorship 9496376Authorship 950136231211490Chen Z, Ok CY, Wang W, Goswami M, Tang G, Routbort M, Jorgensen JL, Medeiros LJ, Wang SACytometry. Part B, Clinical cytometryLow-Grade Myelodysplastic Syndromes with Preserved CD34+ B-Cell Precursors (CD34+ Hematogones). Cytometry B Clin Cytom. 2020 01; 98(1):36-42.Cytometry B Clin Cytom2019-06-18T00:00:002019Low-Grade Myelodysplastic Syndromes with Preserved CD34+ B-Cell Precursors (CD34+ Hematogones).31219818Kim DH, Medeiros LJ, Aung PP, Young KH, Miranda RN, Ok CYThe American journal of surgical pathologyMantle Cell Lymphoma Involving Skin: A Clinicopathologic Study of 37 Cases. Am J Surg Pathol. 2019 10; 43(10):1421-1428.Am J Surg Pathol2019-10-01T00:00:002019Mantle Cell Lymphoma Involving Skin: A Clinicopathologic Study of 37 Cases.Authorship 9507061131243771Hu B, Patel KP, Chen HC, Wang X, Luthra R, Routbort MJ, Kanagal-Shamanna R, Medeiros LJ, Yin CC, Zuo Z, Ok CY, Loghavi S, Tang G, Tambaro FP, Thompson P, Burger J, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating M, Wierda WGBritish journal of haematologyAssociation of gene mutations with time-to-first treatment in 384 treatment-naive chronic lymphocytic leukaemia patients. Br J Haematol. 2019 11; 187(3):307-318.Br J Haematol2019-06-26T00:00:002019Association of gene mutations with time-to-first treatment in 384 treatment-naive chronic lymphocytic leukaemia patients.Authorship 950932331258847Sakhdari A, Moghaddam PA, Ok CY, Walter O, Tomaszewicz K, Caporelli ML, Meng X, LaFemina J, Whalen G, Belkin E, Zivny J, Wassef W, Woda BA, Hutchinson LM, Cosar EFOncotargetSomatic molecular analysis augments cytologic evaluation of pancreatic cyst fluids as a diagnostic tool. Oncotarget. 2019 Jun 18; 10(40):4026-4037.Oncotarget2019-06-18T00:00:002019Somatic molecular analysis augments cytologic evaluation of pancreatic cyst fluids as a diagnostic tool.Authorship 954104331425921Sakhdari A, Tang Z, Ok CY, Bueso-Ramos CE, Medeiros LJ, Huh YOCancer geneticsHomogeneously staining region (hsr) on chromosome 11 is highly specific for KMT2A amplification in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Cancer Genet. 2019 10; 238:18-22.Cancer Genet2019-07-05T00:00:002019Homogeneously staining region (hsr) on chromosome 11 is highly specific for KMT2A amplification in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).Authorship 956082931557598Chen Z, Wang SA, Goswami M, Tang G, Routbort MJ, Patel KP, Luthra R, Medeiros LJ, Ok CYLeukemia researchComparison of therapy-related myelodysplastic syndrome with ring sideroblasts and de novo myelodysplastic syndrome with ring sideroblasts. Leuk Res. 2019 11; 86:106227.Leuk Res2019-09-17T00:00:002019Comparison of therapy-related myelodysplastic syndrome with ring sideroblasts and de novo myelodysplastic syndrome with ring sideroblasts.Authorship 961190131735344Ok CY, Medeiros LJPathologyHigh-grade B-cell lymphoma: a term re-purposed in the revised WHO classification. Pathology. 2020 Jan; 52(1):68-77.Pathology2019-11-15T00:00:002019High-grade B-cell lymphoma: a term re-purposed in the revised WHO classification.Authorship 9621541231804006Sakhdari A, Thakral B, Loghavi S, Kanagal-Shamanna R, Yin CC, Zuo Z, Routbort MJ, Luthra R, Medeiros LJ, Wang SA, Patel KP, Ok CYCancer medicineRAS and TP53 can predict survival in adults with T-cell lymphoblastic leukemia treated with hyper-CVAD. Cancer Med. 2020 02; 9(3):849-858.Cancer Med2019-12-05T00:00:002019RAS and TP53 can predict survival in adults with T-cell lymphoblastic leukemia treated with hyper-CVAD.Authorship 979419432191807Jain P, Zhang S, Kanagal-Shamanna R, Ok CY, Nomie K, Gonzalez GN, Gonzalez-Pagan O, Hill HA, Lee HJ, Fayad L, Westin J, Nastoupil L, Hagemeister F, Chen W, Oriabure O, Badillo M, Jiang C, Yixin Y, Li S, Tang G, Yin CC, Patel KP, Medeiros LJ, Nair R, Ahmed S, Iyer SP, Thirumurthi S, Champlin R, Xu G, Tinsu P, Santos D, Wang R, Han G, Zhang J, Song X, Neelapu S, Romaguera J, Futreal A, Flowers C, Fowler N, Wang L, Wang MLBlood advancesGenomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL. Blood Adv. 2020 03 24; 4(6):1038-1050.Blood Adv2020-03-24T00:00:002020Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL.Authorship 9863161332238878Quesada AE, Montalban-Bravo G, Luthra R, Patel KP, Sasaki K, Bueso-Ramos CE, Khoury JD, Routbort MJ, Bassett R, Hidalgo-Lopez JE, Zhao C, Lin P, Loghavi S, Ok CY, Kadia T, DiNardo CD, Kantarjian H, Garcia-Manero G, Kanagal-Shamanna RModern pathology : an official journal of the United States and Canadian Academy of Pathology, IncClinico-pathologic characteristics and outcomes of the World Health Organization (WHO) provisional entity de novo acute myeloid leukemia with mutated RUNX1. Mod Pathol. 2020 09; 33(9):1678-1689.Mod Pathol2020-04-01T00:00:002020Clinico-pathologic characteristics and outcomes of the World Health Organization (WHO) provisional entity de novo acute myeloid leukemia with mutated RUNX1.32239765Zhao S, Kanagal-Shamanna R, Navsaria L, Ok CY, Zhang S, Nomie K, Han G, Hao D, Hill HA, Jiang C, Yao Y, Nastoupil L, Westin J, Fayad L, Nair R, Steiner R, Ahmed S, Samaniego F, Iyer SP, Oriabure O, Chen W, Song X, Zhang J, Badillo M, Moghrabi O, Aranda J, Tang G, Yin CC, Patel K, Medeiros LJ, Li S, Vega F, Thirumurthi S, Xu G, Neelapu S, Flowers CR, Romaguera J, Fowler N, Wang L, Wang ML, Jain PAmerican journal of hematologyEfficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients. Am J Hematol. 2020 06; 95(6):623-629.Am J Hematol2020-04-17T00:00:002020Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients.Authorship 9872124Authorship 9949951Authorship 995025532694616Ok CY, Trowell KT, Parker KG, Moser K, Weinberg OK, Rogers HJ, Reichard KK, George TI, Hsi ED, Bueso-Ramos CE, Tam W, Orazi A, Bagg A, Arber DA, Hasserjian RP, Wang SAModern pathology : an official journal of the United States and Canadian Academy of Pathology, IncChronic myeloid neoplasms harboring concomitant mutations in myeloproliferative neoplasm driver genes (JAK2/MPL/CALR) and SF3B1. Mod Pathol. 2021 01; 34(1):20-31.Mod Pathol2020-07-21T00:00:002020Chronic myeloid neoplasms harboring concomitant mutations in myeloproliferative neoplasm driver genes (JAK2/MPL/CALR) and SF3B1.32696696Thakral B, Daver N, Tang Z, Patel KP, Ok CY, Loghavi S, Khoury JD, Alotaibi AS, Konopleva M, Yilmaz M, Medeiros LJLeukemia & lymphomaClonal evolution with acquisition of BCR-ABL1 in refractory acute myeloid leukemia post therapy with FLT3-inhibitor. Leuk Lymphoma. 2020 12; 61(13):3243-3246.Leuk Lymphoma2020-07-22T00:00:002020Clonal evolution with acquisition of BCR-ABL1 in refractory acute myeloid leukemia post therapy with FLT3-inhibitor.Authorship 1005071533189964Fang H, Medeiros LJ, Tang Z, Wang W, Ok CY, Patel KP, Khoury JD, Thakral BAnnals of diagnostic pathologyFrom the archives of MD Anderson Cancer Center: Untreated leukemic non-nodal mantle cell lymphoma with relapse as pleomorphic variant mantle cell lymphoma 21 years later. Ann Diagn Pathol. 2021 Feb; 50:151649.Ann Diagn Pathol2020-10-24T00:00:002020From the archives of MD Anderson Cancer Center: Untreated leukemic non-nodal mantle cell lymphoma with relapse as pleomorphic variant mantle cell lymphoma 21 years later.Authorship 1009322733480830Augustyn A, Medeiros LJ, Ludmir EB, Gunther J, Fang P, Li S, Ok CY, Bankston ME, Verma V, Pasalic D, Ahmed S, Nastoupil LJ, Westin JR, Strati P, Neelapu SS, Nair R, Steiner RE, Iyer SP, Rodriguez A, Fayad LE, Flowers CR, Dabaja BS, Pinnix CCLeukemia & lymphomaThe impact of cell-of-origin, MYC/Bcl-2 dual expression and MYC rearrangement on disease relapse among early stage diffuse large B-cell lymphoma patients treated with combined modality therapy. Leuk Lymphoma. 2021 06; 62(6):1361-1369.Leuk Lymphoma2021-01-22T00:00:002021The impact of cell-of-origin, MYC/Bcl-2 dual expression and MYC rearrangement on disease relapse among early stage diffuse large B-cell lymphoma patients treated with combined modality therapy.Authorship 1009885433491779Jain P, Kanagal-Shamanna R, Zhang S, Ok CY, Navsaria L, Nastoupil L, Lee HJ, Tang G, Yin CC, Badillo M, Nair R, Li S, Patel KM, Flowers C, Vega F, Wang L, Wang MLAmerican journal of hematologyOutcomes of relapsed mantle cell lymphoma patients after discontinuing acalabrutinib. Am J Hematol. 2021 05 01; 96(5):E137-E140.Am J Hematol2021-02-11T00:00:002021Outcomes of relapsed mantle cell lymphoma patients after discontinuing acalabrutinib.Authorship 1010417333526873Weinberg OK, Chisholm KM, Ok CY, Fedoriw Y, Grzywacz B, Kurzer JH, Mason EF, Moser KA, Bhattacharya S, Xu M, Babu D, Foucar K, Tam W, Bagg A, Orazi A, George TI, Wang W, Wang SA, Arber DA, Hasserjian RPModern pathology : an official journal of the United States and Canadian Academy of Pathology, IncClinical, immunophenotypic and genomic findings of NK lymphoblastic leukemia: a study from the Bone Marrow Pathology Group. Mod Pathol. 2021 07; 34(7):1358-1366.Mod Pathol2021-02-01T00:00:002021Clinical, immunophenotypic and genomic findings of NK lymphoblastic leukemia: a study from the Bone Marrow Pathology Group.Authorship 10188032134001881Zhang S, Jiang VC, Han G, Hao D, Lian J, Liu Y, Zhang R, McIntosh J, Wang R, Dang M, Dai E, Wang Y, Santos D, Badillo M, Leeming A, Chen Z, Hartig K, Bigcal J, Zhou J, Kanagal-Shamanna R, Ok CY, Lee H, Steiner RE, Zhang J, Song X, Nair R, Ahmed S, Rodriquez A, Thirumurthi S, Jain P, Wagner-Bartak N, Hill H, Nomie K, Flowers C, Futreal A, Wang L, Wang MNature communicationsLongitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphoma. Nat Commun. 2021 05 17; 12(1):2877.Nat Commun2021-05-17T00:00:002021Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphoma.Authorship 10237341734155351Evans MG, Medeiros LJ, Marques-Piubelli ML, Wang HY, Ortiz-Hidalgo C, Pina-Oviedo S, Morine A, Clemens MW, Hunt KK, Iyer S, Hu Q, Recavarren C, Demichelis R, Romero M, Sohani AR, Misialek M, Amin MB, Bueso-Ramos CE, Carballo-Zarate AA, Lee HJ, Ok CY, Xu J, Miranda RNModern pathology : an official journal of the United States and Canadian Academy of Pathology, IncBreast implant-associated anaplastic large cell lymphoma: clinical follow-up and analysis of sequential pathologic specimens of untreated patients shows persistent or progressive disease. Mod Pathol. 2021 12; 34(12):2148-2153.Mod Pathol2021-06-21T00:00:002021Breast implant-associated anaplastic large cell lymphoma: clinical follow-up and analysis of sequential pathologic specimens of untreated patients shows persistent or progressive disease.Authorship 10274661634376807Martinez-Baquero D, Sakhdari A, Mo H, Kim DH, Kanagal-Shamanna R, Li S, Young KH, O'Malley DP, Dogan A, Jain P, Wang ML, McDonnell TJ, Miranda RN, Vega F, Medeiros LJ, Ok CYModern pathology : an official journal of the United States and Canadian Academy of Pathology, IncEZH2 expression is associated with inferior overall survival in mantle cell lymphoma. Mod Pathol. 2021 12; 34(12):2183-2191.Mod Pathol2021-08-10T00:00:002021EZH2 expression is associated with inferior overall survival in mantle cell lymphoma.34416041Wang SA, Ok CY, Kim AS, Lucas F, Morgan EA, Thakral B, Patel S, Nardi V, Patel KM, Weinberg OK, Hasserjian RPAmerican journal of hematologyMyelodysplastic syndromes with no somatic mutations detected by next-generation sequencing display similar features to myelodysplastic syndromes with detectable mutations. Am J Hematol. 2021 11 01; 96(11):E420-E423.Am J Hematol2021-08-30T00:00:002021Myelodysplastic syndromes with no somatic mutations detected by next-generation sequencing display similar features to myelodysplastic syndromes with detectable mutations.Authorship 10286532Authorship 1031987934655612Tashakori M, Kim DH, Kanagal-Shamanna R, Vega F, Miranda RN, Jain P, Wang M, Medeiros LJ, Ok CYHuman pathologyMantle cell lymphoma involving tonsils: a clinicopathologic study of 83 cases. Hum Pathol. 2021 12; 118:60-68.Hum Pathol2021-10-14T00:00:002021Mantle cell lymphoma involving tonsils: a clinicopathologic study of 83 cases.Authorship 10340266Authorship 1034428534767860Qiu L, Xu J, Tang G, Wang SA, Lin P, Ok CY, Garces S, Yin CC, Khanlari M, Vega F, Medeiros LJ, Li SHuman pathologyMantle cell lymphoma with chronic lymphocytic leukemia-like features: a diagnostic mimic and pitfall. Hum Pathol. 2022 01; 119:59-68.Hum Pathol2021-11-09T00:00:002021Mantle cell lymphoma with chronic lymphocytic leukemia-like features: a diagnostic mimic and pitfall.34797699Jain P, Zhao S, Lee HJ, Hill HA, Ok CY, Kanagal-Shamanna R, Hagemeister FB, Fowler N, Fayad L, Yao Y, Liu Y, Moghrabi OB, Navsaria L, Feng L, Nogueras Gonzalez GM, Xu G, Thirumurthi S, Santos D, Iliescu C, Tang G, Medeiros LJ, Vega F, Avellaneda M, Badillo M, Flowers CR, Wang L, Wang MLJournal of clinical oncology : official journal of the American Society of Clinical OncologyIbrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma. J Clin Oncol. 2022 01 10; 40(2):202-212.J Clin Oncol2021-11-19T00:00:002021Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma.Authorship 10366526Authorship 10367311034989420Jelloul FZ, Yang RK, Wang P, Garces S, Kanagal-Shamanna R, Ok CY, Loghavi S, Routbort MJ, Zuo Z, Yin CC, Floyd K, Bassett RL, Wierda WG, Jain N, Thompson PA, Luthra R, Medeiros LJ, Patel KPAmerican journal of hematologyNon-coding NOTCH1 mutations in chronic lymphocytic leukemia negatively impact prognosis. Am J Hematol. 2022 03 01; 97(3):E100-E102.Am J Hematol2022-01-21T00:00:002022Non-coding NOTCH1 mutations in chronic lymphocytic leukemia negatively impact prognosis.34992253El Hussein S, DiNardo CD, Takahashi K, Khoury JD, Fang H, Furudate K, Lyapichev KA, Garces S, Kanagal-Shamanna R, Ok CY, Patel KP, Routbort MJ, Ravandi F, Medeiros LJ, Wang SA, Loghavi SBone marrow transplantationAcquired WT1 mutations contribute to relapse of NPM1-mutated acute myeloid leukemia following allogeneic hematopoietic stem cell transplant. Bone Marrow Transplant. 2022 03; 57(3):370-376.Bone Marrow Transplant2022-01-07T00:00:002022Acquired WT1 mutations contribute to relapse of NPM1-mutated acute myeloid leukemia following allogeneic hematopoietic stem cell transplant.Authorship 1040463735074072Wang ML, Jain P, Zhao S, Lee HJ, Nastoupil L, Fayad L, Ok CY, Kanagal-Shamanna R, Hill HA, Yao Y, Hagemeister FB, Westin JR, Fowler N, Samaniego F, Steiner R, Nair R, Iyer SP, Navsaria L, Badillo M, Mantle Cell Research Group, Feng L, Xuelin H, Nogueras Gonzalez GM, Xu G, Wagner-Bartak N, Thirumurthi S, Santos D, Tang G, Lin P, Wang SA, Jorgensen J, Yin CC, Li S, Patel KP, Vega F, Medeiros LJ, Flowers CR, Wang LThe Lancet. OncologyIbrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (=65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial. Lancet Oncol. 2022 03; 23(3):406-415.Lancet Oncol2022-01-21T00:00:002022Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (=65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial.Authorship 1044016535430388Jelloul FZ, Yang R, Garces S, Kanagal-Shamanna R, Ok CY, Loghavi S, Routbort MJ, Zuo Z, Yin CC, Floyd K, Bassett RL, Wierda W, Jain N, Thompson P, Luthra R, Medeiros LJ, Patel KPLeukemia researchLandscape of NOTCH1 mutations and co-occurring biomarker alterations in chronic lymphocytic leukemia. Leuk Res. 2022 05; 116:106827.Leuk Res2022-03-21T00:00:002022Landscape of NOTCH1 mutations and co-occurring biomarker alterations in chronic lymphocytic leukemia.Authorship 1045028935504958Sakhdari A, Class C, Montalban-Bravo G, Sasaki K, Bueso-Ramos CE, Patel KP, Routbort MJ, Loghavi S, Ok CY, Quesada A, Khoury JD, Konoplev SN, Kantarjian HP, Garcia-Manero G, Medeiros LJ, Kanagal-Shamanna RModern pathology : an official journal of the United States and Canadian Academy of Pathology, IncImmunohistochemical loss of enhancer of Zeste Homolog 2 (EZH2) protein expression correlates with EZH2 alterations and portends a worse outcome in myelodysplastic syndromes. Mod Pathol. 2022 09; 35(9):1212-1219.Mod Pathol2022-05-03T00:00:002022Immunohistochemical loss of enhancer of Zeste Homolog 2 (EZH2) protein expression correlates with EZH2 alterations and portends a worse outcome in myelodysplastic syndromes.Authorship 1047946635690645Tashakori M, Khoury JD, Routbort MJ, Patel KP, Wang SA, Ok CY, El-Hussein S, Kanagal-Shamanna R, Luthra R, Hu S, Lin P, Pemmaraju N, Bose P, Verstovsek S, Bueso-Ramos CE, Medeiros LJ, Loghavi SModern pathology : an official journal of the United States and Canadian Academy of Pathology, IncClinicopathologic spectrum of myeloid neoplasms with concurrent myeloproliferative neoplasm driver mutations and SRSF2 mutations. Mod Pathol. 2022 11; 35(11):1677-1683.Mod Pathol2022-06-11T00:00:002022Clinicopathologic spectrum of myeloid neoplasms with concurrent myeloproliferative neoplasm driver mutations and SRSF2 mutations.36671709Zuo Z, Medeiros LJ, Garces S, Routbort MJ, Ok CY, Loghavi S, Kanagal-Shamanna R, Jelloul FZ, Garcia-Manero G, Chien KS, Patel KP, Luthra R, Yin CCBiologyConcurrent Mutations in SF3B1 and PHF6 in Myeloid Neoplasms. Biology (Basel). 2022 Dec 21; 12(1).Biology (Basel)2022-12-21T00:00:002022Concurrent Mutations in SF3B1 and PHF6 in Myeloid Neoplasms.36513804Li S, Qiu L, Xu J, Lin P, Ok CY, Tang G, McDonnell TJ, James You M, Khanlari M, Miranda RN, Medeiros LJLeukemiaHigh-grade B-cell lymphoma (HGBL)-NOS is clinicopathologically and genetically more similar to DLBCL/HGBL-DH than DLBCL. Leukemia. 2023 02; 37(2):422-432.Leukemia2022-12-13T00:00:002022High-grade B-cell lymphoma (HGBL)-NOS is clinicopathologically and genetically more similar to DLBCL/HGBL-DH than DLBCL.36583229Shuai W, Zuo Z, Li N, Garces S, Jelloul FZ, Ok CY, Li S, Xu J, You MJ, Wang W, Rehder C, Jabbour EJ, Patel KP, Medeiros LJ, Yin CCCancerETNK1 mutation occurs in a wide spectrum of myeloid neoplasms and is not specific for atypical chronic myeloid leukemia. Cancer. 2023 03 15; 129(6):878-889.Cancer2022-12-29T00:00:002022ETNK1 mutation occurs in a wide spectrum of myeloid neoplasms and is not specific for atypical chronic myeloid leukemia.Authorship 10628965Authorship 10628796Authorship 10628905Authorship 1067512936994939Marques-Piubelli ML, Kim DH, Medeiros LJ, Lu W, Khan K, Gomez-Bolanos LI, Rodriguez S, Parra ER, Ok CY, Aradhya A, Solis LM, Nieto YL, Steiner R, Ahmed S, Vega FHistopathologyCD30 expression is frequently decreased in relapsed classic Hodgkin lymphoma after anti-CD30 CAR T-cell therapy. Histopathology. 2023 Jul; 83(1):143-148.Histopathology2023-03-30T00:00:002023CD30 expression is frequently decreased in relapsed classic Hodgkin lymphoma after anti-CD30 CAR T-cell therapy.Authorship 10708501037154083Jelloul FZ, Routbort MJ, DiNardo CD, Bueso-Ramos CE, Kanagal-Shamanna R, Thakral B, Zuo Z, Yin CC, Loghavi S, Ok CY, Wang SA, Tang Z, You MJ, Patel KP, Medeiros LJ, Quesada AEAmerican journal of hematologyDDX41 mutations in patients with non-myeloid hematologic neoplasms. Am J Hematol. 2023 08; 98(8):E193-E196.Am J Hematol2023-05-08T00:00:002023DDX41 mutations in patients with non-myeloid hematologic neoplasms.Authorship 107402713Authorship 1073404337243496Nahmod KA, Sasaki K, Ok CY, Loghavi SAmerican journal of hematologyUtility of p53 immunohistochemistry as a surrogate for sequencing in myeloid neoplasms: A tale of caution. Am J Hematol. 2024 Feb; 99(2):329-330.Am J Hematol2023-05-27T00:00:002023Utility of p53 immunohistochemistry as a surrogate for sequencing in myeloid neoplasms: A tale of caution.37288826Khanlari M, Mo H, Kim DH, Sakhdari A, Young KH, Jain P, Wang M, Li S, Kanagal-Shamanna R, Miranda RN, Vega F, Medeiros LJ, Ok CYThe American journal of surgical pathologyBlastoid and Pleomorphic Mantle Cell Lymphoma Demonstrate Distinct Clinicopathologic and Genetic Features. Am J Surg Pathol. 2023 08 01; 47(8):849-858.Am J Surg Pathol2023-06-08T00:00:002023Blastoid and Pleomorphic Mantle Cell Lymphoma Demonstrate Distinct Clinicopathologic and Genetic Features.Authorship 10793377Authorship 10795003Authorship 1079395437605812Wang SA, Jorgensen JL, Hu S, Jia F, Li S, Loghavi S, Ok CY, Thakral B, Xu J, Medeiros LJ, Wang WCytometry. Part B, Clinical cytometryValidation of a 12-color flow cytometry assay for acute myeloid leukemia minimal/measurable residual disease detection. Cytometry B Clin Cytom. 2023 Sep; 104(5):356-366.Cytometry B Clin Cytom2023-08-22T00:00:002023Validation of a 12-color flow cytometry assay for acute myeloid leukemia minimal/measurable residual disease detection.37543028Siddiqui SH, Thakral B, Aakash F, Ok CY, Tang Z, Medeiros LJAnnals of diagnostic pathologyFrom the archives of MD Anderson Cancer Center: Sporadic Burkitt lymphoma with a complex karyotype and SOX11 expression. Ann Diagn Pathol. 2023 Oct; 66:152182.Ann Diagn Pathol2023-07-21T00:00:002023From the archives of MD Anderson Cancer Center: Sporadic Burkitt lymphoma with a complex karyotype and SOX11 expression.37538987Hill HA, Jain P, Ok CY, Sasaki K, Chen H, Wang ML, Chen KCancer research communicationsIntegrative Prognostic Machine Learning Models in Mantle Cell Lymphoma. Cancer Res Commun. 2023 08; 3(8):1435-1446.Cancer Res Commun2023-08-02T00:00:002023Integrative Prognostic Machine Learning Models in Mantle Cell Lymphoma.Authorship 1081281637821434Jain P, Nomie K, Kotlov N, Segodin V, Hill H, Ok CY, Fetooh A, Kanagal-Shamanna R, Vega F, Bagaev A, Fowler N, Flowers CR, Wang MBlood cancer journalImmune-depleted tumor microenvironment is associated with poor outcomes and BTK inhibitor resistance in mantle cell lymphoma. Blood Cancer J. 2023 10 12; 13(1):156.Blood Cancer J2023-10-12T00:00:002023Immune-depleted tumor microenvironment is associated with poor outcomes and BTK inhibitor resistance in mantle cell lymphoma.Authorship 1088201738301962Quesada AE, Hu S, Li S, Toruner GA, Wei Q, Loghavi S, Ok CY, Jain P, Thakral B, Nwogbo OV, Kim D, Iyer SP, You MJ, Medeiros LJ, Tang GHuman pathologyOptical genomic mapping is a helpful tool for detecting CCND1 rearrangements in CD5-negative small B-cell lymphoma: Two cases of leukemic non-nodal mantle cell lymphoma. Hum Pathol. 2024 Feb; 144:71-76.Hum Pathol2024-01-30T00:00:002024Optical genomic mapping is a helpful tool for detecting CCND1 rearrangements in CD5-negative small B-cell lymphoma: Two cases of leukemic non-nodal mantle cell lymphoma.Authorship 1089313738372648Nwogbo OV, Fang H, Wang W, Xu J, Miranda RN, Bose P, Ok CY, Jorgensen JL, Medeiros LJ, Wang SAAmerican journal of clinical pathologyMulticolor flow cytometric immunophenotyping is highly sensitive and specific in identifying aberrant mast cells in the diagnostic workup of systemic mastocytosis. Am J Clin Pathol. 2024 Feb 19.Am J Clin Pathol2024-02-19T00:00:002024Multicolor flow cytometric immunophenotyping is highly sensitive and specific in identifying aberrant mast cells in the diagnostic workup of systemic mastocytosis.Authorship 10903011238451836Marques-Piubelli ML, Lyapichev KA, Fnu A, Adrada B, Stewart J, Hunt KK, Clemens MW, Iyer S, Wu Y, El Hussein S, Xu J, Ok CY, Li S, M Pierson D, Ferrufino-Schmidt MC, Nahmod KA, Yoga A, Hunsicker L, Evans MG, Resetkova E, Qiu L, Khanlari M, Garces SA, Bueso-Ramos CE, Medeiros LJ, Miranda RNThe American journal of surgical pathologyThe Spectrum of Non-neoplastic Changes Associated With Breast Implants: Histopathology, Imaging, and Clinical Significance. Am J Surg Pathol. 2024 Mar 04.Am J Surg Pathol2024-03-04T00:00:002024The Spectrum of Non-neoplastic Changes Associated With Breast Implants: Histopathology, Imaging, and Clinical Significance.Authorship 10903959Authorship 10903891038460798Kim DH, Siddiqui S, Jain P, Wang M, Thakral B, Li S, Miranda R, Vega F, Medeiros LJ, Ok CYHuman pathologyTP53 mutation is frequent in mantle cell lymphoma with EZH2 expression and have dismal outcome when both are present. Hum Pathol. 2024 Mar 07; 146:1-7.Hum Pathol2024-03-07T00:00:002024TP53 mutation is frequent in mantle cell lymphoma with EZH2 expression and have dismal outcome when both are present.38468555El Dana F, Garces Narvaez SA, El-Mallawany NK, Agrusa JE, Dreyer ZE, Marcogliese AN, Elghetany MT, Punia JN, Ok CY, Patel KP, Lopez-Terrada DH, Fisher KE, Curry CVPediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology SocietyChildhood and Adolescent Relapsed/Refractory Aggressive B-Cell Lymphomas With t(8;14) and BCL2 Expression, Burkitt Lymphoma Versus Diffuse Large B-Cell Lymphoma: A Diagnostic Challenge. Pediatr Dev Pathol. 2024 Mar 11; 10935266241230600.Pediatr Dev Pathol2024-03-11T00:00:002024Childhood and Adolescent Relapsed/Refractory Aggressive B-Cell Lymphomas With t(8;14) and BCL2 Expression, Burkitt Lymphoma Versus Diffuse Large B-Cell Lymphoma: A Diagnostic Challenge.true1ProfessorProfessortrue1Associate ProfessorAssociate Professortrue1Assistant ProfessorAssistant Professortrue1ProfessorProfessortrue1Associate ProfessorAssociate Professortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1Assistant ProfessorAssistant Professortrue1Associate ProfessorAssociate Professor